Menu
← Oncology Approval Tracker
FDA DECISION ·
Brukinsa tablets
zanubrutinib · BeOne Medicines USA
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
A 160 mg tablet formulation with obinutuzumab for adults with relapsed or refractory follicular lymphoma after at least two systemic treatment lines.
LAMPGEN ANALYSIS
Why it matters
This formulation action retains accelerated status for the obinutuzumab combination in relapsed follicular lymphoma.
What research teams should watch
Keep oral dispensing aligned with obinutuzumab visits and record the two qualifying prior systemic treatment lines.
PRIMARY RECORDS